Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis. What immunotherapies for multiple sclerosis are associated with the greatest benefit and highest risk of discontinuation due to adverse events in patients with relapsing-remitting multiple sclerosis?Alemtuzumab, natalizumab, and fingolimod were associated with the greatest benefit with regard to relapse prevention. Their association with prevention of disability worsening was unclear. Fingolimod

Multiple sclerosis following a spinal cord injury: a rare and unfortunate case This is a case report and review of literature with the objective report of the case of a young man with physical disability following a traumatic spinal cord injury (SCI) who was later newly diagnosed with multiple sclerosis (MS) in an inpatient SCI rehabilitation center. (Barcelona, Spain). A 24-year-old male sustained a traumatic spinal cord lesion (T9 AIS A) as the result of a motorcycle accident. He completed (...) MRI revealed multiple demyelinating lesions suggestive of MS. The diagnosis of MS was confirmed by a neurologist and treatment was started with daily doses of glatiramer acetate. At this time the patient was still independent in transfers, activities of daily living and wheelchair management. In young patients with SCI, adequate follow-up is important to detect subsequent complications that may lead to clinical and functional deterioration with a view to uncommon causes such as MS.

Medicines used for Multiple Sclerosis A Health Medicines used for Multiple Sclerosis. A Health - NIPH Selected items added to basket Close Search for: Søk Meny Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close About NIPH Close Medicines used for Multiple Sclerosis. A Health Have you found an error? Order Download: Key message This Health Technology Assessment (...) was commissioned by the “National system for the introduction of new health technologies within the specialist health service”. The aim of this report was to assess the effect and cost-effectiveness of the disease modifying medicines used in Norway for patients with relapsing remitting multiple sclerosis (dimethyl fumarate, teriflunomide, interferon beta, peg-interferon, glatiramer acetate, natalizumab, fingolimod, and alemtuzumab). The key results are: • We identified 37 randomised clinical trials

Daclizumab (Zinbryta) for the treatment of relapsing (recidive) forms of multiple sclerosis (RMS) Daclizumab (Zinbryta®) for the treatment of relapsing (recidive) forms of multiple sclerosis (RMS) | Report | National Health Care Institute You are here: Daclizumab (Zinbryta®) for the treatment of relapsing (recidive) forms of multiple sclerosis (RMS) Search within English part of National Health Care Institute Search Daclizumab (Zinbryta®) for the treatment of relapsing (recidive) forms (...) of multiple sclerosis (RMS) Zorginstituut Nederland carried out a marginal assessment of the medicine daclizumab (Zinbryta ® ), whereby they came to the following conclusion. Based on the criteria of the Medicines Reimbursement System (GVS), daclizumab is interchangeable with interferon beta products (interferon beta-1a, interferon beta-1b, peginterferon beta-1a) and glatiramer acetate (Copaxone ® ), which are included in the GVS. Share this page Service About this site

Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc (...) .. Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Electric Stimulation; Gait Disorders, Neurologic; Humans; Multiple Sclerosis; Peroneal Neuropathies Language Published English Country of organisation United States English summary An English language summary is available. Address

Sodium channel blockers for neuroprotection in multiple sclerosis. Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating disease of the central nervous system (CNS), which can occur in many parts of the CNS and result in a wide range of symptoms including sensory impairment, fatigue, walking or balance problems, visual impairment, vertigo and cognitive disabilities. At present, the most commonly used MS treatments are immunomodulating agents, but they have little effect (...) strategy for preventing disability progression in people with MS.To assess the efficacy and safety of sodium channel blockers for neuroprotection in people with MS to prevent the occurrence of disability and alleviate the burden of the disease.We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register (27 August 2015) which, among other sources, contains references from the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. Daclizumab high-yield process (HYP) is a humanized monoclonal antibody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 signaling. Abnormalities in interleukin-2 signaling have been implicated in the pathogenesis of multiple sclerosis and other autoimmune disorders.We conducted a randomized, double-blind, active-controlled, phase 3 study involving 1841 patients with relapsing (...) -remitting multiple sclerosis to compare daclizumab HYP, administered subcutaneously at a dose of 150 mg every 4 weeks, with interferon beta-1a, administered intramuscularly at a dose of 30 μg once weekly, for up to 144 weeks. The primary end point was the annualized relapse rate.The annualized relapse rate was lower with daclizumab HYP than with interferon beta-1a (0.22 vs. 0.39; 45% lower rate with daclizumab HYP; P<0.001). The number of new or newly enlarged hyperintense lesions on T2-weighted

Guidelines for prescribing disease-modifying treatments in multiple sclerosis Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis Neil Scolding, 1 David Barnes, 2 Sarah Cader, 3 Jeremy Chataway, 4 Abhijit Chaudhuri, 5 Alasdair Coles, 6 Gavin Giovannoni, 7 David Miller, 8 Waqar Rashid, 9 Klaus Schmierer, 10 Abdullah Shehu, 11 Eli Silber, 12 Carolyn Young, 13 John Zajicek 14 ? Additional material is published online (...) -001139 INTRODUCTION In June 1999, the Association of British Neurologists (ABN) first published guide- lines for the use of the licensed multiple sclerosis (MS) disease-modifying treat- ments (at that time ß-interferon and gla- tiramer acetate). The guidelines were revised in 2001 and have been periodic- ally updated since then. In 2002, follow- ing the negative assessment of these treatments by the National Institute for Health and Care Excellence (NICE), the MS risk-sharing scheme started, in which

Effect of comorbidity on mortality in multiple sclerosis We aimed to compare survival in the multiple sclerosis (MS) population with a matched cohort from the general population, and to evaluate the association of comorbidity with survival in both populations.Using population-based administrative data, we identified 5,797 persons with MS and 28,807 controls matched on sex, year of birth, and region. We estimated annual mortality rates. Using Cox proportional hazards regression, we evaluated

Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis Butler M, Forte ML, Schwehr N, Carpenter A, Kane RL Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Butler M, Forte ML, Schwehr N, Carpenter A, Kane RL. Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 150. 2015 Authors' objectives We conducted a systematic review to examine the long-term consequences of discontinuing disease-modifying treatment (DMT) for multiple sclerosis (MS) by examining the long

Telerehabilitation for persons with multiple sclerosis. Telerehabilitation, an emerging method, extends rehabilitative care beyond the hospital, and facilitates multifaceted, often psychotherapeutic approaches to modern management of patients using telecommunication technology at home or in the community. Although a wide range of telerehabilitation interventions are trialed in persons with multiple sclerosis (pwMS), evidence for their effectiveness is unclear.To investigate the effectiveness (...) and safety of telerehabilitation intervention in pwMS for improved patient outcomes. Specifically, this review addresses the following questions: does telerehabilitation achieve better outcomes compared with traditional face-to-face intervention; and what types of telerehabilitation interventions are effective, in which setting and influence which specific outcomes (impairment, activity limitation and participation)?We performed a literature search using the Cochrane Multiple Sclerosis and Rare Diseases

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial To assess long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS).Patients completing FTY720 Research Evaluating Effects of Daily Oral Therapy in MS (FREEDOMS) were eligible for this dose-blinded, parallel-group extension study, continuing fingolimod 0.5 mg/day or 1.25 mg/day, or switching from placebo to either dose, randomized 1:1. Efficacy

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis The Cannabinoid Use (...) in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, Zajicek J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made

Multiple sclerosis: neither natalizumab nor alemtuzumab Prescrire IN ENGLISH - Spotlight ''Multiple sclerosis: neither natalizumab nor alemtuzumab'', 1 March 2015 {1} {1} {1} | | > > > Multiple sclerosis: neither natalizumab nor alemtuzumab Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Multiple sclerosis: neither natalizumab nor alemtuzumab (...) With the benefit of hindsight, natalizumab (Tysabri°) has proved even more toxic than expected in multiple sclerosis patients. Evaluation of alemtuzumab (Lemtrada°) is too biased for its potential usefulness to be judged, however it exposes patients to severe adverse effects. The reference treatment for relapsing-remitting multiple sclerosis which progresses in flare-ups is interferon beta injection, for lack of anything better. In 2007, in severe multiple sclerosis when interferon beta does not seem

Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. Case reports have suggested a link between human papillomavirus (HPV) vaccination and development of multiple sclerosis and other demyelinating diseases.To investigate if quadrivalent HPV (qHPV) vaccination is associated with an increased risk of multiple sclerosis and other demyelinating diseases.Using nationwide registers we identified a cohort of all females aged 10 (...) years to 44 years in Denmark and Sweden, followed up from 2006 to 2013, information on qHPV vaccination, and data on incident diagnoses of multiple sclerosis and other demyelinating diseases. The primary analysis used a cohort design including vaccinated and unvaccinated study participants. A secondary analysis used a self-controlled case-series design including only cases. Both analyses used a 2-year risk period following vaccination.Information on qHPV vaccination was obtained through the national

Management of Multiple Sclerosis Management of Multiple Sclerosis Published by: Malaysia Health Technology Assessment Section (MaHTAS) Medical Development Division, Ministry of Health Malaysia Level 4, Block E1, Precinct 1 Federal Government Administrative Centre 62590, Putrajaya, Malaysia Copyright The copyright owner of this publication is MaHTAS. Content may be reproduced in any number of copies and in any format or medium provided that a copyright acknowledgement to MaHTAS is included (...) of the related specialty will be informed about it. A discussion will be done on the need for a revision including the scope of the revised CPG. A multidisciplinary team will be formed and the latest systematic review methodology used by MaHTAS will be employed. Management of Multiple Sclerosis TABLE OF CONTENTS No. Title Page Levels of Evidence & Formulation of Recommendation i Guidelines Development and Objectives ii Guidelines Development Group v Review Committee vi External Reviewers vii Algorithm 1

Depression in Multiple Sclerosis IDENTIFICATION AND MANAGEMENT OF DEPRESSION IN MULTIPLE SCLEROSIS Clinical Practice Guideline | December 2015 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. OBJECTIVE Alberta clinicians have the skills and tools to assess, diagnose, treat and manage depression (...) in patients with multiple sclerosis (MS) within primary care. TARGET POPULATION Adults 18 years of age and older EXCLUSIONS Children less than 18 years of age RECOMMENDATIONS PRACTICE POINT Be aware that depression is two to three times more common in MS patients than in the general population and can go undetected. Be aware that the suicide rate in people with MS is approximately twice that of the general population. Therefore it is important to be vigilant for depression in patients with MS. X DO

Rehabilitation in multiple sclerosis Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share November 24, 2015 ; 85 (21) Special Article Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis Report of the Guideline Development, Dissemination, and Implementation (...) Getchius Gary Gronseth Melissa J. Armstrong Pushpa Narayanaswami Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis Jodie K. Haselkorn , Christina Hughes , Alex Rae-Grant , Lily Jung Henson , Christopher T. Bever , Albert C. Lo , Theodore R. Brown , George H. Kraft , Thomas Getchius , Gary Gronseth , Melissa J. Armstrong , Pushpa Narayanaswami Neurology Nov 2015, 85 (21) 1896-1903; DOI: 10.1212/WNL.0000000000002146 Citation Manager Formats Make Comment See Comments

Cohort study: The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases Article Text

Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Biotin (Cerenday) for primary (...) and secondary progressive multiple sclerosis - first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Cerenday (biotin) is a high dose oral formulation of biotin, a water soluble vitamin that acts as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acid synthesis. Very high doses of biotin may be efficacious in multiple sclerosis (MS) by promoting myelin repair through activation of acetyl-CoA carboxylase